Tscan Therapeutics Inc (NASDAQ: TCRX) on Tuesday, plunged -28.23% from the previous trading day, before settling in for the closing price of $4.64. Within the past 52 weeks, TCRX’s price has moved between $3.92 and $9.69.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 230.91% over the last five years. The company achieved an average annual earnings per share of 6.43%. With a float of $43.47 million, this company’s outstanding shares have now reached $49.08 million.
The firm has a total of 154 workers. Let’s measure their productivity. In terms of profitability, gross margin is 61.01%, operating margin of -1276.07%, and the pretax margin is -1188.88%.
Tscan Therapeutics Inc (TCRX) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Tscan Therapeutics Inc is 18.56%, while institutional ownership is 74.09%. The most recent insider transaction that took place on Nov 15 ’24, was worth 4,114. In this transaction 10% Owner of this company bought 947 shares at a rate of $4.34, taking the stock ownership to the 5,225,547 shares. Before that another transaction happened on Sep 23 ’24, when Company’s Director bought 5,000 for $5.29, making the entire transaction worth $26,450. This insider now owns 45,000 shares in total.
Tscan Therapeutics Inc (TCRX) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 6.43% per share during the next fiscal year.
Tscan Therapeutics Inc (NASDAQ: TCRX) Trading Performance Indicators
Tscan Therapeutics Inc (TCRX) is currently performing well based on its current performance indicators. A quick ratio of 9.56 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.99.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.94, a number that is poised to hit -0.32 in the next quarter and is forecasted to reach -1.28 in one year’s time.
Technical Analysis of Tscan Therapeutics Inc (TCRX)
Analysing the last 5-days average volume posted by the [Tscan Therapeutics Inc, TCRX], we can find that recorded value of 0.61 million was better than the volume posted last year of 0.25 million. As of the previous 9 days, the stock’s Stochastic %D was 38.67%. Additionally, its Average True Range was 0.42.
During the past 100 days, Tscan Therapeutics Inc’s (TCRX) raw stochastic average was set at 3.07%, which indicates a significant decrease from 7.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 155.09% in the past 14 days, which was higher than the 77.06% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $4.96, while its 200-day Moving Average is $6.47. Now, the first resistance to watch is $4.29. This is followed by the second major resistance level at $5.26. The third major resistance level sits at $5.80. If the price goes on to break the first support level at $2.78, it is likely to go to the next support level at $2.24. Now, if the price goes above the second support level, the third support stands at $1.27.
Tscan Therapeutics Inc (NASDAQ: TCRX) Key Stats
Market capitalization of the company is 177.72 million based on 53,371K outstanding shares. Right now, sales total 21,050 K and income totals -89,220 K. The company made 1,050 K in profit during its latest quarter, and -29,890 K in sales during its previous quarter.
